文献速递消化道肿瘤与早癌

鸡乳杆菌来源代谢物通过调节IDO1/Kyn/AHR轴抑制调节性T细胞增强结直肠癌抗PD1疗效

Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis.
PubMed 文献 · Gut · 2023-11-24

本研究在同基因小鼠模型和偶氮甲烷/葡聚糖硫酸钠诱导的结直肠癌模型中,评估益生菌鸡乳杆菌对抗PD1疗效的影响。鸡乳杆菌显著提高不同微卫星不稳定状态(MC38为MSI高,CT26为MSI低)小鼠模型的抗PD1疗效,并减少瘤内Foxp3+ CD25+调节性T细胞浸润、增强CD8+ T细胞效应功能。其功能代谢物吲哚-3-羧酸通过抑制IDO1表达、竞争性拮抗Kyn与AHR结合,抑制Treg分化,从而增强抗PD1疗效。

要点

  • 鸡乳杆菌在MSI高(MC38)和MSI低(CT26)同基因小鼠模型中显著提高抗PD1疗效。
  • 鸡乳杆菌与抗PD1协同减少瘤内Foxp3+ CD25+ Treg浸润并增强CD8+ T细胞效应功能。
  • 鸡乳杆菌来源吲哚-3-羧酸通过IDO1/Kyn/AHR轴抑制Treg分化,补充Kyn可逆转其效应。

核心结论

  • 鸡乳杆菌来源的吲哚-3-羧酸通过调节IDO1/Kyn/AHR轴抑制CD4+ Treg分化并增强CD8+ T细胞功能,从而改善结直肠癌抗PD1疗效。
  • 鸡乳杆菌是增强抗PD1疗效的潜在佐剂。

研究设计与样本

  • 在同基因小鼠模型和偶氮甲烷/葡聚糖硫酸钠诱导的结直肠癌模型中评估鸡乳杆菌对抗PD1反应的影响。
  • 采用多色流式细胞术识别免疫格局变化,并通过免疫组织化学染色和体外功能实验验证。
  • 采用液相色谱-质谱联用鉴定功能代谢物。

主要发现

  • 鸡乳杆菌在两种不同微卫星不稳定状态的同基因小鼠模型(MC38为MSI高,CT26为MSI低)中显著改善抗PD1疗效。
  • 该效应在结直肠癌肿瘤发生模型中得到证实。
  • 鸡乳杆菌与抗PD1协同减少瘤内Foxp3+ CD25+调节性T细胞浸润,并增强CD8+ T细胞的效应功能。
  • 鸡乳杆菌来源的吲哚-3-羧酸被鉴定为功能代谢物,其抑制IDO1表达从而抑制肿瘤中Kyn产生。
  • 吲哚-3-羧酸与Kyn竞争AHR结合位点并拮抗Kyn与CD4+ T细胞结合,从而在体外抑制Treg分化。

临床怎么用

  • 作者认为鸡乳杆菌是增强结直肠癌抗PD1疗效的潜在佐剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gut microbiota is a key player in dictating immunotherapy response. We aimed to explore the immunomodulatory effect of probiotic Lactobacillus gallinarum and its role in improving anti-programmed cell death protein 1 (PD1) efficacy against colorectal cancer (CRC). DESIGN: The effects of L. gallinarum in anti-PD1 response were assessed in syngeneic mouse models and azoxymethane/dextran sulfate sodium-induced CRC model. The change of immune landscape was identified by multicolour flow cytometry and validated by immunohistochemistry staining and in vitro functional assays. Liquid chromatography-mass spectrometry was performed to identify the functional metabolites. RESULTS: L. gallinarum significantly improved anti-PD1 efficacy in two syngeneic mouse models with different microsatellite instability (MSI) statuses (MSI-high for MC38, MSI-low for CT26). Such effect was confirmed in CRC tumourigenesis model. L. gallinarum synergised with anti-PD1 therapy by reducing Foxp3+ CD25+ regulatory T cell (Treg) intratumoural infiltration, and enhancing effector function of CD8+ T cells. L. gallinarum-derived indole-3-carboxylic acid (ICA) was identified as the functional metabolite. Mechanistically, ICA inhibited indoleamine 2,3-dioxygenase (IDO1) expression, therefore suppressing kynurenine (Kyn) production in tumours. ICA also competed with Kyn for binding site on aryl hydrocarbon receptor (AHR) and antagonised Kyn binding on CD4+ T cells, thereby inhibiting Treg differentiation in vitro. ICA phenocopied L. gallinarum effect and significantly improved anti-PD1 efficacy in vivo, which could be reversed by Kyn supplementation. CONCLUSION: L. gallinarum-derived ICA improved anti-PD1 efficacy in CRC through suppressing CD4+Treg differentiation and enhancing CD8+T cell function by modulating the IDO1/Kyn/AHR axis. L. gallinarum is a potential adjuvant to augment anti-PD1 efficacy against CRC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Fong W, Li Q, Ji F, et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis. Gut. 2023. PMID: 37770127. doi:10.1136/gutjnl-2023-329543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。